Kura Oncology (KUR) Stock Forecast & Price Target

Compare

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KUR Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Kura

Oncology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KUR Stock 12 Month Forecast

Average Price Target

€24.49

▲(224.75% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is €24.49 with a high forecast of €34.81 and a low forecast of €13.05. The average price target represents a 224.75% change from the last price of €7.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","11":"€11","19":"€19","27":"€27","35":"€35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.806398,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€34.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.486300993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.05239925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11,19,27,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,9.371569076923077,11.491138153846155,13.610707230769231,15.730276307692307,17.849845384615385,19.969414461538463,22.088983538461537,24.208552615384615,26.328121692307693,28.44769076923077,30.567259846153846,32.686828923076924,{"y":34.806398,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,8.577715461,9.903430922,11.229146383,12.554861844000001,13.880577305,15.206292766,16.532008227000002,17.857723688,19.183439149,20.50915461,21.834870071,23.160585532000002,{"y":24.486300993,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.252,7.698184557692308,8.144369115384615,8.590553673076922,9.036738230769231,9.482922788461538,9.929107346153845,10.375291903846154,10.821476461538461,11.267661019230768,11.713845576923077,12.160030134615386,12.606214692307692,{"y":13.05239925,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.648,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.256,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.996,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.644,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.176,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.788,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.966,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.612,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€34.81

Average Price Target€24.49

Lowest Price Target€13.05

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Dai

UBS

€13.85→€12.98

Buy

72.20%

Upside

Assigned

03/13/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)

Etzer Darout

Barclays

€24.24

Buy

221.44%

Upside

Reiterated

03/06/26

Analysts Conflicted on These Healthcare Names: Atea Pharmaceuticals (NASDAQ: AVIR), InnovAge Holding (NASDAQ: INNV) and Kura Oncology (NASDAQ: KURA)

Jason Zemansky

Bank of America Securities

€25.97

Buy

244.40%

Upside

Reiterated

03/06/26

Kura Oncology price target raised to $30 from $29 at BofAKura Oncology price target raised to $30 from $29 at BofA

Robert Driscoll

Wedbush

€32.89→€31.16

Buy

313.28%

Upside

Reiterated

03/06/26

Kura Oncology price target lowered to $36 from $38 at WedbushKura Oncology price target lowered to $36 from $38 at Wedbush

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

03/06/26

Kura Oncology (KURA) Receives a Hold from Guggenheim

Charles Zhu

LifeSci Capital

€24.24

Buy

221.44%

Upside

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX) and Kura Oncology (NASDAQ: KURA)

Joseph Pantginis

H.C. Wainwright

€34.62

Buy

359.21%

Upside

Reiterated

03/05/26

Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

03/05/26

Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook

Jonathan Chang

Leerink Partners

€21.64→€17.31

Buy

129.60%

Upside

Reiterated

01/13/26

Kura Oncology (KURA) Receives a Buy from Leerink Partners

Roger Song

Jefferies

€24.24

Buy

221.44%

Upside

Reiterated

12/10/25

Kura Oncology (KURA) Gets a Buy from Jefferies

Justin Zelin

BTIG

―

Hold

―

Reiterated

12/09/25

BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)

Reni Benjamin

Citizens JMP

€20.77

Buy

175.52%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMP

Mara Goldstein

Mizuho Securities

€25.97

Buy

244.40%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

€8.66→€6.92

Hold

-8.16%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Dai

UBS

€13.85→€12.98

Buy

72.20%

Upside

Assigned

03/13/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)

Etzer Darout

Barclays

€24.24

Buy

221.44%

Upside

Reiterated

03/06/26

Analysts Conflicted on These Healthcare Names: Atea Pharmaceuticals (NASDAQ: AVIR), InnovAge Holding (NASDAQ: INNV) and Kura Oncology (NASDAQ: KURA)

Jason Zemansky

Bank of America Securities

€25.97

Buy

244.40%

Upside

Reiterated

03/06/26

Kura Oncology price target raised to $30 from $29 at BofAKura Oncology price target raised to $30 from $29 at BofA

Robert Driscoll

Wedbush

€32.89→€31.16

Buy

313.28%

Upside

Reiterated

03/06/26

Kura Oncology price target lowered to $36 from $38 at WedbushKura Oncology price target lowered to $36 from $38 at Wedbush

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

03/06/26

Kura Oncology (KURA) Receives a Hold from Guggenheim

Charles Zhu

LifeSci Capital

€24.24

Buy

221.44%

Upside

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX) and Kura Oncology (NASDAQ: KURA)

Joseph Pantginis

H.C. Wainwright

€34.62

Buy

359.21%

Upside

Reiterated

03/05/26

Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

03/05/26

Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook

Jonathan Chang

Leerink Partners

€21.64→€17.31

Buy

129.60%

Upside

Reiterated

01/13/26

Kura Oncology (KURA) Receives a Buy from Leerink Partners

Roger Song

Jefferies

€24.24

Buy

221.44%

Upside

Reiterated

12/10/25

Kura Oncology (KURA) Gets a Buy from Jefferies

Justin Zelin

BTIG

―

Hold

―

Reiterated

12/09/25

BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)

Reni Benjamin

Citizens JMP

€20.77

Buy

175.52%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMP

Mara Goldstein

Mizuho Securities

€25.97

Buy

244.40%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

€8.66→€6.92

Hold

-8.16%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

3 Months

xxx

Success Rate

12/23 ratings generated profit

Average Return

+10.71%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +10.71% per trade.

1 Year

Robert DriscollWedbush

Success Rate

12/23 ratings generated profit

Average Return

+17.57%

reiterated a buy rating 12 days ago

Copying Robert Driscoll's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +17.57% per trade.

2 Years

xxx

Success Rate

11/23 ratings generated profit

Average Return

-5.80%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.83% of your transactions generating a profit, with an average return of -5.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KUR Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KUR has received 17 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. KUR average Analyst price target in the past 3 months is 24.49.

Each month's total comprises the sum of three months' worth of ratings.

KUR Financial Forecast

KUR Earnings Forecast

Next quarter’s earnings estimate for KUR is -€0.70 with a range of -€0.90 to €0.41. The previous quarter’s EPS was -€0.80. KUR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year KUR has Performed in-line its overall industry.

KUR Sales Forecast

Next quarter’s sales forecast for KUR is €22.70M with a range of €1.48M to €121.82M. The previous quarter’s sales results were €15.09M. KUR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year KUR has Performed in-line its overall industry.

KUR Stock Forecast FAQ

What is DE:KUR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kura Oncology’s 12-month average price target is 24.49.

What is DE:KUR’s upside potential, based on the analysts’ average price target?

Kura Oncology has 224.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Kura Oncology a Buy, Sell or Hold?

Kura Oncology has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Kura Oncology’s share price target?

The average share price target for Kura Oncology is 24.49. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €34.81 ,and the lowest forecast is €13.05. The average share price target represents 224.75% Increase from the current price of €7.54.

What do analysts say about Kura Oncology?

Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Kura Oncology?

To buy shares of DE:KUR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Kura Oncology (KUR) Stock Forecast & Price Target

KUR Analyst Ratings

KUR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kura Oncology

KUR Analyst Recommendation Trends

KUR Financial Forecast

KUR Earnings Forecast

KUR Sales Forecast

KUR Stock Forecast FAQ

Detailed List of Analyst Forecasts